Trial Profile
A retrospective study comparing pre-and post-procedure angiographic outcomes in acute coronary syndrome (ACS) patients receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2018
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- 31 Oct 2018 New trial record
- 25 Sep 2018 Results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics